atrasentan has been researched along with Cells, Neoplasm Circulating in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agarwal, N; Carducci, MA; Cote, RJ; Datar, RH; Ely, B; Fink, LM; Garzotto, M; Goldkorn, A; Higano, CS; Hussain, M; Lara, P; Mack, PC; Monk, JP; Quinn, DI; Tangen, CM; Thompson, IM; Twardowski, P; Van Veldhuizen, PJ; Vogelzang, NJ; Xu, T | 1 |
| Fong, L; Friedlander, TW | 1 |
1 trial(s) available for atrasentan and Cells, Neoplasm Circulating
| Article | Year |
|---|---|
Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.
Topics: Aged; Antineoplastic Agents; Atrasentan; Biomarkers, Tumor; Castration; Cell Count; Disease Progression; Docetaxel; Double-Blind Method; Drug Therapy, Combination; Humans; Male; Middle Aged; Neoplasm Grading; Neoplastic Cells, Circulating; Prognosis; Prostatic Neoplasms; Pyrrolidines; Taxoids; Treatment Outcome | 2014 |
1 other study(ies) available for atrasentan and Cells, Neoplasm Circulating
| Article | Year |
|---|---|
The end of the beginning: circulating tumor cells as a biomarker in castration-resistant prostate cancer.
Topics: Antineoplastic Agents; Atrasentan; Docetaxel; Humans; Male; Neoplastic Cells, Circulating; Prostatic Neoplasms; Pyrrolidines; Taxoids | 2014 |